Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial]
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Udenafil (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- Acronyms ULTIMATE-HFpEF
- 07 Jun 2017 Biomarkers information updated
- 04 Oct 2012 Planned end date changed from 1 Mar 2013 to 1 May 2013 as reported by ClinicalTrials.gov record.
- 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.